Skip to main content

Dr. Iskra Pusic, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
29
In the NPI registry since
2008
Medicare patients seen, 2024
250

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    MO license 2008009983

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
250
Services billed
22,933
Patients’ average age
70
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram12,24015
Injection, ferric carboxymaltose, 1 mg9,00012
Injection, daratumumab, 10 mg and hyaluronidase-fihj3,78013
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg1,47015
Injection, dexamethasone sodium phosphate, 1 mg72239
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes47685
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg40825
Injection, palonosetron hcl, 25 mcg24016
Injection, granisetron hydrochloride, 100 mcg22017
Established patient office or other outpatient visit, 30-39 minutes16664

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Acyclovir
Other prescribers in Saint Louis, MO
86
Oxycodone Hcl
Other prescribers in Saint Louis, MO
75
Valacyclovir (valacyclovir hcl)
Other prescribers in Saint Louis, MO
44
Fluconazole
Other prescribers in Saint Louis, MO
44
Jakafi (ruxolitinib phosphate)43
Ciprofloxacin Hcl
Other prescribers in Saint Louis, MO
41
Venclexta (venetoclax)34
Gabapentin
Other prescribers in Saint Louis, MO
30
Rezurock (belumosudil mesylate)30
Bosulif (bosutinib)27

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 3 companies reported 12 payments worth $12,319 in total to this clinician.

By company
Genzyme Corporation$10,673
National Marrow Donor Program$1,525
Jazz Pharmaceuticals Inc.$121
By type
Consulting Fee$10,451
Travel and Lodging$1,165
Food and Beverage$703

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jun 14, 2025Genzyme Corporation
Jun 14, 2025
Consulting Fee$9,251
Jun 7, 2025Genzyme Corporation
Jun 7, 2025
Travel and Lodging
travel to San Francisco, CA · in-kind
$771
Jan 17, 2025National Marrow Donor Program
Jan 17, 2025
Consulting Fee$400
Jun 20, 2025National Marrow Donor Program
Jun 20, 2025
Consulting Fee$400
Oct 24, 2025National Marrow Donor Program
Oct 24, 2025
Consulting Fee$400
Jun 7, 2025Genzyme Corporation
Jun 7, 2025
Travel and Lodging
travel to San Francisco, CA · in-kind
$330
Jun 14, 2025Genzyme Corporation
Jun 14, 2025
Travel and Lodging
travel to San Francisco, CA
$65.04

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Missouri →

Industry-funded research

Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $150,024 in research payments for these studies, mostly to the institutions running them.

  • A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
    Incyte Corporation
  • AGAVE-201, a phase 2, open-label, randomized, multicenter study to evaluate the efficacy, safety and tolerability of axatilimab at 3 different doses in patients with recurrent or refractory active chronic graft versus…
    Syndax Pharmaceuticals, Inc.
  • A study to evaluate vimseltinib in adults with active chronic graft-versus-host disease (cgvhd)
    Deciphera Pharmaceuticals Inc.
  • A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia
    National Marrow Donor Program
  • A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic…
    National Marrow Donor Program
  • Facilitating Activation of Study Trials (FAST)
    National Marrow Donor Program

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Saint Louis

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 17, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1164699161. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.